Physician profile
Avinash Thomas
NPI 1447744594
$7,710.49
in general payments reported to CMS, 2019-2025
43 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $783 · 2022: $1,871 · 2023: $1,733 · 2024: $2,265 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,056.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,283.35 | 2021-2024 | |
| Emd Serono, INC. | $720.44 | 2022-2024 | Mavenclad |
| Amneal Pharmaceuticals LLC | $707.76 | 2021-2023 | Rytary |
| Lundbeck LLC | $561.66 | 2023-2025 | Vyepti |
| Kyowa Kirin, INC. | $296.35 | 2022-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $248.12 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $232.37 | 2025 | Symbravo |
| Janssen Pharmaceuticals, INC | $211.38 | 2021-2025 | Spravato |
| Alexion Pharmaceuticals, INC. | $207.40 | 2022-2024 | Soliris, Ultomiris |
| Davol INC. | $159.65 | 2024 | Arista Ah Flexitip |
| Kerecis Limited | $150.00 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.99 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $132.76 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Depuy Synthes Sales INC. | $125.87 | 2024 | Symphony, Conduit, Teligen |
| Astrazeneca Pharmaceuticals Lp | $124.12 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $122.13 | 2023 | Pico |
| Amgen INC. | $110.94 | 2022-2025 | Uplizna |
| Pfizer INC. | $107.07 | 2024 | |
| Celgene Corporation | $105.50 | 2025 | Zeposia |
| My01 INC. | $90.25 | 2023 | My01 Continuous Compartmental Pressure Monitor |
| Genzyme Corporation | $76.86 | 2021-2022 | |
| Lilly USA, LLC | $75.56 | 2021-2022 | |
| Biogen, INC. | $62.53 | 2021-2023 | Spinraza |
| Solventum Corporation | $60.37 | 2025 | V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice |
| Baxter Healthcare | $54.61 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Avion Pharmaceuticals | $52.76 | 2022-2023 | Dhivy, Methylphenidate Hydrochloride |
| Vanda Pharmaceuticals INC. | $48.56 | 2024-2025 | Hetlioz, Fanapt |
| Alnylam Pharmaceuticals INC. | $47.02 | 2021-2023 | Givlaari |
| Allergan, INC. | $39.63 | 2021 | |
| Alfasigma USA, INC. | $31.98 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $31.05 | 2023 | Ingrezza |
| Vertex Pharmaceuticals Incorporated | $30.73 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.91 | 2023 | |
| Acadia Pharmaceuticals INC | $27.45 | 2025 | Nuplazid |
| Aprecia Pharmaceuticals, LLC | $27.12 | 2022 | |
| Abbott Laboratories | $24.68 | 2023 | Infinity |
| Csl Behring | $23.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.43 | 2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $19.04 | 2021 | |
| Grt US Holding, INC. | $18.43 | 2021 | |
| Medtronic, INC. | $17.28 | 2024 | Percept Pc Brainsense |
| Imperative Care, INC | $15.63 | 2023 | Zoom 88-T Large Distal Platform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.